Trelegy Ellipta 25 ug/1

Trelegy Ellipta 25 ug/1 is a combination inhaler containing fluticasone furoate, umeclidinium bromide, and vilanterol trifenatate. This respiratory medication is designed for long-term maintenance treatment of conditions like chronic obstructive pulmonary disease (COPD).

Trelegy Ellipta 25 ug/1 is primarily used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It combines three active ingredients to help manage symptoms such as wheezing, shortness of breath, and coughing. This inhaler is not intended for immediate relief of sudden breathing problems but rather for ongoing management of respiratory conditions.

Common effects of Trelegy Ellipta 25 ug/1 may include throat irritation, headache, and a dry mouth. Some users might experience hoarseness or a taste disturbance. These effects are generally mild and temporary, but if they persist or worsen, it is advisable to consult a healthcare provider.

Trelegy Ellipta 25 ug/1 should be used as directed by a healthcare professional. It is important to follow the prescribed dosage and administration instructions. Patients with a history of asthma, heart conditions, or severe allergies should discuss their medical history with their healthcare provider before using this medication. Always store the inhaler in a clean, dry place and keep it out of reach of children.

Trelegy Ellipta 25 ug/1 may interact with other medications, including beta-blockers, diuretics, and certain antidepressants. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Additionally, consuming alcohol while using this inhaler may increase the risk of side effects.